The words came one per second, fifteen concrete nouns read aloud, and the people sitting in the testing room at the Warneford Hospital were asked to hand them straight back. Then again. Five times over. It is a deceptively plain task, the kind of thing that sounds easy until you try it, and for people who have been through depression it is often quietly harder than it should be. Some of them, on this particular fortnight, were doing rather better than expected.
What none of them knew was which bottle of capsules they had been taking. Half had been swallowing a drug licensed for chronic constipation.
The drug is prucalopride, and it does its everyday work in the gut, nudging a sluggish bowel along by tickling a particular serotonin receptor, the fourth one, known to the trade as 5-HT4. That same receptor turns up in the brain, dotted through the hippocampus and the temporal lobe, regions that handle the laying down of memory. Researchers from the University of Birmingham and the University of Oxford wondered whether a medicine already sitting on pharmacy shelves for one purpose might, almost by accident, be doing something useful upstairs. The hunch was not random. A decade of animal work, and a handful of earlier human studies, had been pointing this way.
Cognitive trouble in depression goes by a friendlier name when patients describe it. Brain fog: the thinking that comes slow, the plans that slip, the word that will not surface.
It is far more common than the public conversation about depression tends to admit. Around 80 per cent of people in a depressive episode report difficulties with memory or concentration, and, more stubbornly, over 40 per cent are still reporting them after their mood has lifted and the formal diagnosis no longer applies. First-line antidepressants, for the most part, leave this particular symptom largely untouched.
“Cognitive problems, or brain fog, are an important and often overlooked feature of depression, and can persist even when mood improves,” says Dr Angharad de Cates of the University of Birmingham, who led the work. “Our study suggests that a targeted serotonin 5-HT4 receptor medication, already used for chronic constipation, may improve cognitive functioning in people with a history of depression.”
What the capsules actually did
The trial was modest by design and careful in execution. Fifty volunteers, aged 18 to 40, each with at least two past depressive episodes but well clear of the most recent one for six months or more and on no medication, were randomly assigned to take either 2 mg of prucalopride a day or a placebo of lactose tablets, for somewhere between seven and ten days. Neither the participants nor the people testing them knew who was on what. Before and after, everyone worked through a battery of cognitive tasks: recalling those spoken word lists, holding symbols in mind on a working-memory test that ratchets up in difficulty, reading faces flashed on a screen for half a second. The people on prucalopride remembered more of the words. They answered the working-memory task faster without getting sloppier, and they read the faces more accurately. Pooled across the non-emotional tests, the drug group came out both quicker and more correct, with composite scores landing at z = +0.59 for accuracy and z = -0.69 for speed.
Curiously, the speed effect cut both ways depending on the task. On the emotional tasks, the prucalopride group was actually slower, which the researchers read not as a deficit but as something closer to care, more deliberate, more accurate responding rather than a fog of hesitation.
A different lever from the usual antidepressants
And here is the part that makes the pharmacologists sit up. The drug barely touched emotional processing at all. Conventional antidepressants tend to work by quietly retuning how the brain weighs emotional information, the threat in a face, the negative word; prucalopride seems to leave that machinery alone while improving the cold, unemotional business of remembering and attending. That hints at a genuinely separate mechanism. The animal evidence offers a candidate: in rodents, switching on the 5-HT4 receptor pushes up levels of BDNF, a protein involved in growing and maintaining neural connections, within a few doses rather than the several weeks an SSRI typically needs. There is also the gut to think about, since the overwhelming majority of the body’s serotonin is made there, and the gut-brain conversation may turn out to matter more than anyone expected.
The caveats are real and the team is upfront about them. This was a small, mechanistic study, the sample skewed female, white, highly educated and under 40, and the dosing ran for barely more than a week, so whether the benefit holds, grows, or fades over months is simply unknown.
Still, the safety picture was reassuring; the drug is already licensed, the dose is the one already in use, and the gut effects stayed mild. “Participants didn’t experience any serious gut complaints, because prucalopride works as a laxative gently stimulating bowel movements,” de Cates notes, with the faint air of someone heading off the obvious question.
What gives the finding its weight is the link between lingering brain fog and the risk of falling ill again. Cognitive impairment after recovery is not just an inconvenience; it tracks with a higher chance of relapse, which means a drug that lifts it might do more than help someone find their keys. “For many people, recovery from depression is incomplete because difficulties with memory and concentration persist,” says Professor Susannah Murphy of the University of Oxford, the study’s senior author. “This study provides early evidence that 5-HT4 receptor agonists could help restore aspects of cognitive function, opening an exciting new direction for treatment development.” Because cognitive deficits also shadow schizophrenia and bipolar disorder, the implications may reach well beyond depression.
None of this means a constipation drug is about to be rebadged for the mind tomorrow. But it does mean a receptor in the gut, of all places, has earned a longer look from the people trying to mend the parts of recovery that the current drugs leave behind.
DOI / Source: https://doi.org/10.1017/S0033291726104450
Frequently Asked Questions
Is it true that a laxative can improve memory?
In this trial, yes, at least on several measures. The drug prucalopride, licensed for chronic constipation, improved word recall, working-memory speed and face recognition in people who had recovered from depression. The benefit came from the drug acting on a serotonin receptor that exists in the brain as well as the gut, not from its laxative effect.
How does a constipation drug end up affecting the brain?
Prucalopride switches on the 5-HT4 serotonin receptor. That receptor sits in the gut, where it speeds up bowel movements, but it also appears in memory regions of the brain such as the hippocampus. Animal studies suggest activating it raises a protein called BDNF that helps maintain neural connections, and it does so within a few doses rather than the weeks an ordinary antidepressant takes.
Why does brain fog in depression matter so much?
Difficulties with memory and concentration affect most people during a depressive episode and linger in more than 40 per cent even after their mood recovers. Crucially, this lingering impairment is linked to a higher risk of relapse, so a treatment that lifts it could improve long-term outcomes rather than just day-to-day functioning.
Could prucalopride be prescribed for depression now?
Not yet. This was a small, short study in a fairly narrow group of mostly young, well-educated participants, and it tested only about a week of dosing. Larger and longer trials in more diverse and clinically affected groups are needed before any change to how the drug is used.
